Trident Lifeline Limited , a prominent player in the pharmaceutical sector, has announced its financial results for the first quarter, showcasing strong performance across key metrics. The company's Board of Directors approved the un-audited standalone and consolidated financial results.

Standalone Financial Highlights

• Net sales for Q1 stood at Rs 2,084.65 lacs, reflecting the company's solid market presence.
• The company reported a net profit of Rs 347.59 lacs for the quarter, demonstrating effective cost management and operational efficiency.

Consolidated Financial Performance

• On a consolidated basis, Trident Lifeline reported net sales of Rs 3,401.07 lacs, indicating strong performance across its subsidiaries.
• Consolidated net profit reached Rs 306.28 lacs, showcasing the company's ability to generate profits at the group level.

The consolidated results include the financial performance of Trident Lifeline's subsidiaries, namely TNS Pharma Pvt. Ltd., TLL Parenterals Ltd., TLL Elements Private Ltd., Trident Mediquip Ltd., and TLL Herbal Ltd.

Corporate Updates

In addition to the financial results, the Board of Directors made several key decisions:

1. Appointment of Secretarial Auditor: The Board approved the appointment of M/s. Amareliya & Associates, Practicing Company Secretary, as the Secretarial Auditor for a five-year term. This appointment is subject to shareholder approval at the upcoming Annual General Meeting.

2. Investor Relations: The company reported that no investor complaints were pending during the quarter, reflecting strong investor relations management.

Trident Lifeline's strong quarterly performance, coupled with strategic corporate actions, positions the company for continued growth in the pharmaceutical sector. The appointment of a new Secretarial Auditor also underscores the company's focus on maintaining robust corporate governance practices.

Trident Lifeline Limited , a prominent player in the pharmaceutical sector, has announced a significant move to bolster its capital base and fuel future growth. The company's Board of Directors, in a meeting held on April 16, 2025, approved the issuance of fully convertible warrants on a preferential basis, potentially raising up to ₹26.57 crore.

Key Highlights of the Board Meeting

• Warrant Issue: The board approved the creation, issuance, and allotment of up to 9,99,000 fully convertible warrants.
• Conversion Terms: Each warrant is convertible into one fully paid-up equity share of the company.
• Issue Price: The warrants are priced at ₹266.00 each, including a premium of ₹256.00 per warrant.
• Target Investors: The warrants will be offered to both Promoter/Promoter Group and Non-Promoter/Public categories.
• Conversion Period: Warrant holders have up to 18 months from the date of allotment to exercise their conversion option.

Financial Implications

The preferential issue, if fully subscribed and converted, could inject up to ₹26,57,34,000 into the company's coffers. This move is expected to strengthen Trident Lifeline's financial position and provide capital for potential expansion plans or debt reduction.

Changes in Share Capital

In conjunction with the warrant issue, the board has also approved an increase in the company's Authorized Share Capital:

• Current: ₹12.00 crore (1,20,00,000 equity shares of ₹10.00 each)
• Proposed: ₹15.00 crore (1,50,00,000 equity shares of ₹10.00 each)

This increase is subject to shareholder approval.

Impact on Shareholding Pattern

Post-conversion of all warrants, the company's shareholding structure is expected to undergo slight changes:

Regulatory Compliance and Next Steps

The preferential issue is subject to necessary regulatory approvals and shareholders' consent. To this end, Trident Lifeline has scheduled an Extraordinary General Meeting (EGM) for May 9, 2025, to be held via video conferencing.

The company has appointed National Securities Depository Limited (NSDL) as the Remote E-Voting Agency and M/s. Mittal V Kothari & Associates as the scrutinizer for the EGM proceedings.

Conclusion

This strategic move by Trident Lifeline underscores the company's commitment to growth and its confidence in future prospects. Investors and market watchers will be keenly observing how the company utilizes this potential capital infusion to drive value creation in the coming months.